Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 90 | ECE2023 | Next issue

25th European Congress of Endocrinology

Istanbul, Turkey
13 May 2023 - 16 May 2023

Card image cap
ECE 2023 will be held in Istanbul, Turkey from 13-16 May 2023. Istanbul is known for its rich culture, historical sites and dynamic nightlife, and we are excited to come together in this city, and look forward to meeting old friends, making new ones, and sharing science, collaborations and ideas.

Rapid Communications

Rapid Communications 6: Endocrine-related Cancer

ea0090rc6.1 | Rapid Communications 6: Endocrine-related Cancer | ECE2023

Aberrant activation of Wnt/β-Catenin signaling pathway drives the expression of poor prognosis-associated microRNAs in adrenocortical cancer

Cristante Justine , El Sayed Soha Reda , Denis Josiane , Ragazzon Bruno , Constanze Hantel , Chabre Olivier , Guyon Laurent , Cherradi Nadia

Adrenocortical carcinoma (ACC) is a rare malignancy with dismal prognosis. Deregulated microRNA (miRNA) expression has been implicated in ACC aggressiveness. Nevertheless, the mechanisms underlying such deregulations remain unknown. Aberrant Wnt/β-Catenin signaling has been reported in about 40% of ACC and is associated with poor outcome. In the present work, we aimed to investigate the link between constitutive activation of Wnt/β-Catenin pathway and miRNA expressio...

ea0090rc6.2 | Rapid Communications 6: Endocrine-related Cancer | ECE2023

Refocusing on somatostatin receptors as clinical targets in pheochromocytomas and paragangliomas

Garcia Vioque Victor , Trinidad Moreno Montilla Maria , Blazquez Encinas Rey Ricardo , Mangili Federica , Martinez Montes Angel Mario , Alors-Perez Emilia , Culler Michael D , Pedraza-Arevalo Sergio , Robledo Mercedes , P. Castano Justo , Ibanez Costa Alejandro

Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine neoplasms (NENs) that arise in the adrenal medulla and paraganglia, respectively. As occurs in the rest of NENs, PPGLs commonly present a high density of somatostatin receptors (SSTs) on their membrane. However, unlike in most NENs, somatostatin analogues (SSAs) do not represent a suitable therapeutic target in PPGLs, and the mechanisms underlying this mismatch are still unclear. In this study, we aim to iden...

ea0090rc6.3 | Rapid Communications 6: Endocrine-related Cancer | ECE2023

Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain

Lamas Cristina , Remon Pablo , Soto-Moreno Alfonso , Fajardo-Montanana Carmen , Biagetti Betina , Guerrero Fernando , Castro Marta Araujo , Mora Mireia , Hanzu Felicia Alexandra , Iglesias Pedro , Garcia Centeno Rogelio , Camara-Gomez Rosa

Introduction: Current guidelines propose temozolomide (TMZ) as the first-line chemotherapy for aggressive pituitary neuroendocrine tumors (PitNETs), but no clinical trials have been conducted and clinical experience in this context is limited.Patients and methods: A retrospective study of patients with aggressive pitNETs treated with TMZ was conducted by the members of the Neuroendocrinology Working Area of the Spanish Society of Endocrinology and Nutrit...

ea0090rc6.4 | Rapid Communications 6: Endocrine-related Cancer | ECE2023

Much more than hormonal resistance: estrogen receptor activating mutations mediate chemotherapy resistance in breast cancer

Taya Marwa , Merenbakh-Lamin Keren , Honig Zohar , Wolf Ido , Rubinek Tami

Resistance to endocrine treatment develops with time in virtually all patients with metastatic breast cancer (BC), and eventually most of them are treated with chemotheray. Our group and others discovered a group of mutations in the ligand binding domain (LBD) of the estrogen receptor (ER), that are the direct cause of resistance in ~40% of the patients. The most common mutations are Y537S and D538G ER. Clinical data indicate an association between those ER mutations worse pro...

ea0090rc6.5 | Rapid Communications 6: Endocrine-related Cancer | ECE2023

The frequency of differentiated thyroid carcinoma recurrence in retrospective analysis of 3087 consecutive patients

Palyga Iwona , Rumian Maciej , Kosel Alicja , Albrzykowski Maciej , Krawczyk Paulina , Kalwat Agata , Gąsior-Perczak Danuta , Walczyk Agnieszka , Kuchareczko Artur , Kopczyński Janusz , Chrapek Magdalena , Gozdz Stanislaw , Kowalska Aldona

Introduction: An increase in the incidence of differentiated thyroid cancer (DTC) has been observed in recent decades. Despite the excellent prognosis, DTC patients remain on lifelong oncologic follow-up after treatment, due to fear of recurrence.Aim: Was to evaluate the frequency of real recurrence, defined as appearance of structural or biochemical disease after >12 month period of no evidence of disease (NED) in DTC patients.<p class="abstext"...

ea0090rc6.6 | Rapid Communications 6: Endocrine-related Cancer | ECE2023

C-peptide level concomitant with hypoglycemia gives better performances than insulin for the diagnosis of endogenous hyperinsulinism: a monocentric study of 159 fasting trials

Fideline Bonnet , Devin Clara , Thomeret Louis , Laguillier-Morizot Christelle , Leguy Marie-Clemence , Vaczlavik Anna , Bouys Lucas , Zientek Corinne , Bricaire Leopoldine , Bessiene Laura , Guignat Laurence , Libe Rossella , Mosnier-Pudar Helen , Assie Guillaume , Groussin Lionel , Guibourdenche Jean , Bertherat Jerome

Introduction: The gold standard for insulinoma diagnosis is still 72-hours fasting trial with the aim to trigger Whipple’s triad. In this context, biological diagnosis of endogenous hyperinsulinism relies on the occurrence of a hypoglycemia, concomitant with inadequate high insulin and C-peptide levels. However, diagnostic cut-offs are not consensual among the different learned societies (Endocrine Society 2009, NANETS 2010, ENETS 2012). The objective of this wor...